We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
Cap. Flow
-$23.9M
Cap. Flow %
-0.91%
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.5M
2
SYK icon
Stryker
SYK
+$12.2M
3
AZN icon
AstraZeneca
AZN
+$12.1M
4
DHR icon
Danaher
DHR
+$11.9M
5
PFE icon
Pfizer
PFE
+$11.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.6M
2
SHPG
Shire pic
SHPG
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.3M
4
ABT icon
Abbott
ABT
+$10.4M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 92.61%
2 Real Estate 3%
3 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
101
DELISTED
TESARO, Inc.
TSRO
$4.22M 0.16%
94,970
+37,375
+65% +$1.82M
OVID icon
102
Ovid Therapeutics
OVID
$442M
$4.18M 0.16%
535,824
– –
ARNA
103
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.09M 0.16%
93,767
+76,940
+457% +$3.31M
SNR
104
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$4M 0.15%
528,919
-355,000
-40% -$2.82M
VRNA
105
DELISTED
Verona Pharma
VRNA
$3.78M 0.14%
275,000
– –
IONS icon
106
Ionis Pharmaceuticals
IONS
$8.81B
$3.45M 0.13%
82,838
-82,839
-50% -$3.67M
CLVS
107
DELISTED
Clovis Oncology, Inc.
CLVS
$3.43M 0.13%
75,400
– –
PTLA
108
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.4M 0.13%
89,978
– –
CHRS icon
109
Coherus Oncology
CHRS
$227M
$3.37M 0.13%
240,843
+59,820
+33% +$856K
ARGX icon
110
argenx
ARGX
$54.6B
$3.23M 0.12%
38,931
– –
WHWK
111
Whitehawk Therapeutics
WHWK
$190M
$3.17M 0.12%
+51,000
New +$3.08M
TLGT
112
DELISTED
Teligent, Inc
TLGT
$3.14M 0.12%
90,636
+35,493
+64% +$1.12M
TTPH
113
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.07M 0.12%
42,966
– –
ZTS icon
114
Zoetis
ZTS
$31.9B
$3.05M 0.12%
+35,760
New +$3.02M
PRAH
115
DELISTED
PRA Health Sciences, Inc.
PRAH
$3.03M 0.12%
32,460
– –
VAR
116
DELISTED
Varian Medical Systems, Inc.
VAR
$2.98M 0.11%
26,227
+21,162
+418% +$2.53M
ASND icon
117
Ascendis Pharma A/S
ASND
$16.5B
$2.92M 0.11%
43,914
+37,700
+607% +$2.48M
WELL icon
118
Welltower
WELL
$170B
$2.86M 0.11%
45,560
+24,160
+113% +$1.35M
TRIL
119
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.81M 0.11%
468,399
– –
PRGO icon
120
Perrigo
PRGO
$1.43B
$2.72M 0.1%
37,300
– –
HZNP
121
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.7M 0.1%
162,900
– –
GBT
122
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.68M 0.1%
59,390
-70,558
-54% -$3.21M
AFMD
123
DELISTED
Affimed
AFMD
$2.68M 0.1%
162,479
-18,053
-10% -$380K
AKBA icon
124
Akebia Therapeutics
AKBA
$362M
$2.66M 0.1%
266,612
+133,763
+101% +$1.34M
EVH icon
125
Evolent Health
EVH
$358M
$2.58M 0.1%
122,500
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
  • Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
  • Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
  • Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.